The TOR pathway: A target for cancer therapy

被引：1140

作者：

Bjornsti, MA ^{[1
]}

Houghton, PJ ^{[1
]}

机构：

[1] St Jude Childrens Res Hosp, Dept Mol Pharmacol, Memphis, TN 38105 USA

来源：

NATURE REVIEWS CANCER | 2004年 / 4卷 / 05期

关键词：

D O I：

10.1038/nrc1362

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Rapamycin, a macrocyclic lactone, is a highly specific inhibitor of the serine/threonine protein kinase target of rapamycin (TOR). Although it is clear that TOR controls initiation of protein translation, recent results indicate that TOR is a central controller, integrating a plethora of signalling pathways that respond to growth factors and nutritional status. In addition to the role of rapamycin as an immune suppressant, emerging data indicate that genetic and metabolic changes accompanying malignant transformation might cause hypersensitivity to TOR inhibition.

引用

页码：335 / 348

页数：14

共 187 条

[1] Translational regulation of ribonucleotide reductase by eukaryotic initiation factor 4E links protein synthesis to the control of DNA replication [J].

Abid, MR ;

Li, Y ;

Anthony, C ;

De Benedetti, A .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (50) :35991-35998

[2] Identification of TOR signaling complexes: more TORC for the cell growth engine [J].

Abraham, RT .

CELL, 2002, 111 (01) :9-12

[3] A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets [J].

Arsham, AM ;

Howell, JJ ;

Simon, MC .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (32) :29655-29660

[4] Tuberin, the tuberous sclerosis complex 2 tumor suppressor gene product, regulates Rho activation, cell adhesion and migration [J].

Astrinidis, A ;

Cash, TP ;

Hunter, DS ;

Walker, CL ;

Chernoff, J ;

Henske, EP .

ONCOGENE, 2002, 21 (55) :8470-8476

[5] Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma [J].

Atkins, MB ;

Hidalgo, M ;

Stadler, WM ;

Logan, TF ;

Dutcher, JP ;

Hudes, GR ;

Park, Y ;

Lion, SH ;

Marshall, B ;

Boni, JP ;

Dukart, G ;

Sherman, ML .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :909-918

[6] Interleukin-7 promotes survival and cell cycle progression of T-cell acute lymphoblastic leukemia cells by down-regulating the cyclin-dependent kinase inhibitor p27kip1 [J].

Barata, JT ;

Cardoso, AA ;

Nadler, LM ;

Boussiotis, VA .

BLOOD, 2001, 98 (05) :1524-1531

[7] Overexpression of the eukaryotic translation initiation factor 4G (eIF4G-1) in squamous cell lung carcinoma [J].

Bauer, C ;

Brass, N ;

Diesinger, I ;

Kayser, K ;

Grässer, FA ;

Meese, E .

INTERNATIONAL JOURNAL OF CANCER, 2002, 98 (02) :181-185

[8]

Berkel HJ, 2001, CANCER EPIDEM BIOMAR, V10, P663

[9] Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells [J].

Boulay, A ;

Zumstein-Mecker, S ;

Stephan, C ;

Beuvink, I ;

Zilbermann, F ;

Haller, R ;

Tobler, S ;

Heusser, C ;

O'Reilly, T ;

Stolz, B ;

Marti, A ;

Thomas, G ;

Lane, HA .

CANCER RESEARCH, 2004, 64 (01) :252-261

[10] A MAMMALIAN PROTEIN TARGETED BY G1-ARRESTING RAPAMYCIN-RECEPTOR COMPLEX [J].

BROWN, EJ ;

ALBERS, MW ;

SHIN, TB ;

ICHIKAWA, K ;

KEITH, CT ;

LANE, WS ;

SCHREIBER, SL .

NATURE, 1994, 369 (6483) :756-758

← 1 2 3 4 5 6 7 8 9 10 →